1,893 Shares in Danaher Co. (NYSE:DHR) Acquired by Central Valley Advisors LLC

Central Valley Advisors LLC acquired a new stake in shares of Danaher Co. (NYSE:DHR) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,893 shares of the conglomerate’s stock, valued at approximately $438,000.

Other institutional investors and hedge funds have also modified their holdings of the company. BKM Wealth Management LLC acquired a new position in Danaher during the 4th quarter valued at about $27,000. Wetzel Investment Advisors Inc. acquired a new stake in Danaher during the 4th quarter valued at $29,000. Rakuten Securities Inc. acquired a new stake in Danaher during the 4th quarter valued at $36,000. Financial Connections Group Inc. acquired a new stake in shares of Danaher during the fourth quarter worth $41,000. Finally, Northwest Financial Advisors acquired a new stake in shares of Danaher during the fourth quarter worth $48,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Danaher

In other Danaher news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Rainer Blair sold 9,005 shares of the business’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the sale, the chief executive officer now owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the transaction, the director now directly owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The disclosure for this sale can be found here. Over the last three months, insiders sold 172,540 shares of company stock valued at $43,523,481. Corporate insiders own 10.90% of the company’s stock.

Danaher Price Performance

NYSE:DHR traded up $0.83 during trading hours on Wednesday, hitting $267.38. 1,437,994 shares of the stock were exchanged, compared to its average volume of 2,686,209. The company has a market cap of $198.05 billion, a P/E ratio of 45.18, a P/E/G ratio of 4.11 and a beta of 0.83. The firm’s fifty day moving average price is $249.30 and its 200 day moving average price is $237.84. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $268.98. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. During the same quarter in the prior year, the company earned $2.36 earnings per share. The company’s revenue was down 2.6% on a year-over-year basis. As a group, equities research analysts anticipate that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on DHR shares. Raymond James boosted their price target on Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Bank of America increased their price target on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. Barclays increased their price objective on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 24th. KeyCorp raised their price objective on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Finally, Robert W. Baird raised their price objective on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $267.31.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.